OncoSec Medical Inc. (ONCS.OB) is an advanced-stage biomedical company focused on commercializing therapeutic oncology products. OncoSec is committed to bringing patients new and improved treatment alternatives to existing therapies that have untoward side-effects or where improvements to the patient’s treatment and personal well-being are both desirable and achievable.
OMI’s core technology is a novel delivery system using a form of cell membrane stimulation known as electroporation. Using this system to deliver a proven chemotherapy or an immunotherapy, these therapies can effectively treat cancerous tumors and cancerous cells in the predominantly healthy tissue around the tumor while reducing or eliminating detrimental treatment outcomes associated with other “standard of care” therapies.
When a chemotherapeutic or immunotherapeutic agent is first locally injected into a selected tumor and surrounding tissue, the subsequent application of electroporation causes temporary pores in the cell membrane that allows significantly increased entry of these agents into the cell. The agents can then perform their intended function: the chemotherapeutic will kill rapidly dividing cells, i.e. cancerous cells; the immunotherapy will stimulate the body’s immune system in order to enhance its cancer-killing capabilities.
OMI’s near-term development and commercialization goals are to seek marketing approval in Europe and initiate pivotal clinical trials in the US by 2012.
Specialties
Oncology Therapeutics, Medical Device, Drug Development
